Annexon reports all 10 GBS patients in FORWARD study improved within days on tanruprubart

Annexon, Inc.

All 10 patients showed rapid, clinically meaningful muscle strength improvement within 4 days of single 30 mg/kg infusion.
Four bedbound patients walked with/without assistance between day 2 and day 8; one ventilated patient off ventilator within 4 days.
Results consistent with Phase 3 data where ~90% improved by day 8; tanruprubart generally well-tolerated.
BLA submission targeted for Q4 2026; MAA under EMA review; GBS has ~22,000 annual U.S./Europe cases and >$20B U.S. burden.
CEO cites decade-long commitment to C1q-targeted approach for neuroinflammatory diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.